{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05805501",
      "orgStudyIdInfo": {
        "id": "BO43936"
      },
      "organization": {
        "fullName": "Hoffmann-La Roche",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma",
      "officialTitle": "A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma"
    },
    "statusModule": {
      "statusVerifiedDate": "2026-02",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2023-04-21",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2026-10-31",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2026-10-31",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2023-03-28",
      "studyFirstSubmitQcDate": "2023-03-28",
      "studyFirstPostDateStruct": {
        "date": "2023-04-10",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2026-02-10",
      "lastUpdatePostDateStruct": {
        "date": "2026-02-12",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Hoffmann-La Roche",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC)."
    },
    "conditionsModule": {
      "conditions": [
        "Renal Cell Carcinoma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 199,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Arm A (Tobemstomig + Axitinib)",
          "type": "EXPERIMENTAL",
          "description": "Participants will receive intravenous (IV) tobemstomig every three weeks (Q3W) on Day 1 of each 21-day cycle. Participants will also receive oral (PO) axitinib twice daily (BID).",
          "interventionNames": [
            "Drug: Tobemstomig",
            "Drug: Axitinib"
          ]
        },
        {
          "label": "Arm B (Tobemstomig + Tiragolumab + Axitinib)",
          "type": "EXPERIMENTAL",
          "description": "Participants will receive IV tobemstomig followed by IV tiragolumab Q3W on Day 1 of 21-day cycle. Participants will also receive axitinib PO BID.",
          "interventionNames": [
            "Drug: Tobemstomig",
            "Drug: Tiragolumab",
            "Drug: Axitinib"
          ]
        },
        {
          "label": "Control Arm (Pembrolizumab + Axitinib)",
          "type": "ACTIVE_COMPARATOR",
          "description": "Participants will receive IV pembrolizumab Q3W on Day 1 of each 21-day cycle. Participants will also receive axitinib PO BID.",
          "interventionNames": [
            "Drug: Pembrolizumab",
            "Drug: Axitinib"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Tobemstomig",
          "description": "Participants will receive IV tobemstomig Q3W.",
          "armGroupLabels": [
            "Arm A (Tobemstomig + Axitinib)",
            "Arm B (Tobemstomig + Tiragolumab + Axitinib)"
          ],
          "otherNames": [
            "RO7247669"
          ]
        },
        {
          "type": "DRUG",
          "name": "Tiragolumab",
          "description": "Participants will receive IV tiragolumab Q3W.",
          "armGroupLabels": [
            "Arm B (Tobemstomig + Tiragolumab + Axitinib)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Pembrolizumab",
          "description": "Participants will receive IV pembrolizumab Q3W.",
          "armGroupLabels": [
            "Control Arm (Pembrolizumab + Axitinib)"
          ],
          "otherNames": [
            "Keytruda"
          ]
        },
        {
          "type": "DRUG",
          "name": "Axitinib",
          "description": "Participants will receive axitinib PO BID.",
          "armGroupLabels": [
            "Arm A (Tobemstomig + Axitinib)",
            "Arm B (Tobemstomig + Tiragolumab + Axitinib)",
            "Control Arm (Pembrolizumab + Axitinib)"
          ],
          "otherNames": [
            "Inlyta"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Incidence and Severity of Adverse Events (AEs)",
          "timeFrame": "Up to a maximum of 2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* International Metastatic RCC Database Consortium (IMDC) risk intermediate (score of 1 or 2) or poor (score of 3-6)\n* Measurable disease with at least one measurable lesion\n* Histologically confirmed ccRCC with or without sarcomatoid features\n* Negative for HIV, hepatitis B, or hepatitis C virus (HCV)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 90 days after the final dose of tiragolumab, 4 months after the final dose of tobemstomig (RO7249669) and pembrolizumab, or for 1 week after the final dose of axitinib, whichever occurs last\n* Inability to swallow a tablet or malabsorption syndrome\n* Prior treatment for localized and/or metastatic RCC with systemic RCC-directed therapy, including T-cell costimulating or immune checkpoint blockade therapies\n* Ongoing use or anticipated need for treatment with a strong CYP3A4/5 inhibitor or inducer\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n* Moderate to severe hepatic impairment (Child-Pugh B or C)\n* Uncontrolled hypertension\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* Significant cardiovascular/cerebrovascular disease within 3 months (12 months for UK participants) prior to randomization\n* History of clinically significant ventricular dysrhythmias or risk factors for ventricular dysrhythmias\n* History of congenital QT syndrome\n* Resting heart rate (HR) \\> 100 bpm (or clinically significant tachycardia)\n* Stroke (including transient ischemic attack), myocardial infarction, or other symptomatic ischemic event, or thromboembolic event (e.g., deep venous thrombosis \\[DVT\\], pulmonary embolism \\[PE\\]) within 3 months (12 months for UK participants) before randomization\n* Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1\n* Tumors invading pulmonary blood vessels, cavitating pulmonary lesions or known endobronchial disease\n* Tumor invading the gastrointestinal (GI) tract, including abdominal or tracheoesophageal fistulas\n* Evidence of abdominal free air not explained by paracentesis or recent surgical procedure\n* Active peptic ulcer disease, acute pancreatitis, acute obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction\n* Intra-abdominal abscess within 6 months before initiation of study treatment\n* Clinical signs or symptoms of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding\n* Evidence of bleeding diathesis or significant coagulopathy\n* Grade ≥ 3 hemorrhage or bleeding event within 28 days prior to initiation of study treatment\n* Clinically significant hematuria, hematemesis, hemoptysis of \\> 0.5 teaspoon (2.5 mL) of red blood, coagulopathy, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 3 months before initiation of study treatment\n* Active or history of autoimmune disease or immune deficiency\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* History of another primary malignancy other than RCC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%)\n* Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study\n* Active tuberculosis (TB)\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Participants with active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Known hypersensitivity to Chinese hamster \\*ovary cell products or to any component of tobemstomig, tiragolumab, pembrolizumab, or axitinib",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Clinical Trials",
          "affiliation": "Hoffmann-LaRoche",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "University of Alabama at Birmingham",
          "city": "Birmingham",
          "state": "Alabama",
          "zip": "35294",
          "country": "United States",
          "geoPoint": {
            "lat": 33.52066,
            "lon": -86.80249
          }
        },
        {
          "facility": "UC Irvine Medical Center",
          "city": "Orange",
          "state": "California",
          "zip": "92868",
          "country": "United States",
          "geoPoint": {
            "lat": 33.78779,
            "lon": -117.85311
          }
        },
        {
          "facility": "Sibley Memorial Hospital",
          "city": "Washington D.C.",
          "state": "District of Columbia",
          "zip": "20016",
          "country": "United States",
          "geoPoint": {
            "lat": 38.89511,
            "lon": -77.03637
          }
        },
        {
          "facility": "Emory University",
          "city": "Atlanta",
          "state": "Georgia",
          "zip": "30322",
          "country": "United States",
          "geoPoint": {
            "lat": 33.749,
            "lon": -84.38798
          }
        },
        {
          "facility": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
          "city": "Baltimore",
          "state": "Maryland",
          "zip": "21287",
          "country": "United States",
          "geoPoint": {
            "lat": 39.29038,
            "lon": -76.61219
          }
        },
        {
          "facility": "SCRI Oncology Partners",
          "city": "Nashville",
          "state": "Tennessee",
          "zip": "37203",
          "country": "United States",
          "geoPoint": {
            "lat": 36.16589,
            "lon": -86.78444
          }
        },
        {
          "facility": "Vanderbilt University Medical Center",
          "city": "Nashville",
          "state": "Tennessee",
          "zip": "37232",
          "country": "United States",
          "geoPoint": {
            "lat": 36.16589,
            "lon": -86.78444
          }
        },
        {
          "facility": "UT Southwestern Medical Center",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75390-9179",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Sunshine Coast University Hospital",
          "city": "Birtinya",
          "state": "Queensland",
          "zip": "4575",
          "country": "Australia",
          "geoPoint": {
            "lat": -26.74322,
            "lon": 153.11913
          }
        },
        {
          "facility": "Peking University First Hospital",
          "city": "Beijing",
          "zip": "100034",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Beijing Cancer Hospital",
          "city": "Beijing",
          "zip": "100142",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School",
          "city": "Nanjing",
          "zip": "210008",
          "country": "China",
          "geoPoint": {
            "lat": 32.06167,
            "lon": 118.77778
          }
        },
        {
          "facility": "Tianjin Cancer Hospital",
          "city": "Tianjin",
          "zip": "300060",
          "country": "China",
          "geoPoint": {
            "lat": 39.14222,
            "lon": 117.17667
          }
        },
        {
          "facility": "Institut Sainte Catherine",
          "city": "Avignon",
          "zip": "84918",
          "country": "France",
          "geoPoint": {
            "lat": 43.94834,
            "lon": 4.80892
          }
        },
        {
          "facility": "CHU Besançon - Hôpital Jean Minjoz",
          "city": "Besançon",
          "zip": "25030",
          "country": "France",
          "geoPoint": {
            "lat": 47.24878,
            "lon": 6.01815
          }
        },
        {
          "facility": "CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre",
          "city": "Bordeaux",
          "zip": "33075",
          "country": "France",
          "geoPoint": {
            "lat": 44.84124,
            "lon": -0.58046
          }
        },
        {
          "facility": "Centre Francois Baclesse",
          "city": "Caen",
          "zip": "14076",
          "country": "France",
          "geoPoint": {
            "lat": 49.18585,
            "lon": -0.35912
          }
        },
        {
          "facility": "Centre Leon Berard",
          "city": "Lyon",
          "zip": "69373",
          "country": "France",
          "geoPoint": {
            "lat": 45.74906,
            "lon": 4.84789
          }
        },
        {
          "facility": "Institut Gustave Roussy",
          "city": "Villejuif",
          "zip": "94800",
          "country": "France",
          "geoPoint": {
            "lat": 48.7939,
            "lon": 2.35992
          }
        },
        {
          "facility": "Universitätsklinikum \"Carl Gustav Carus\"",
          "city": "Dresden",
          "zip": "01307",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.05089,
            "lon": 13.73832
          }
        },
        {
          "facility": "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II",
          "city": "Hamburg",
          "zip": "20246",
          "country": "Germany",
          "geoPoint": {
            "lat": 53.55073,
            "lon": 9.99302
          }
        },
        {
          "facility": "Medizinische Hochschule Hannover",
          "city": "Hanover",
          "zip": "30625",
          "country": "Germany",
          "geoPoint": {
            "lat": 52.37052,
            "lon": 9.73322
          }
        },
        {
          "facility": "Klinikum rechts der Isar der TU München",
          "city": "München",
          "zip": "81675",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.60698,
            "lon": 13.31243
          }
        },
        {
          "facility": "Studienpraxis Urologie",
          "city": "Nürtingen",
          "zip": "72622",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.62565,
            "lon": 9.34203
          }
        },
        {
          "facility": "Universitätsklinikum Ulm",
          "city": "Ulm",
          "zip": "89081",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.39841,
            "lon": 9.99155
          }
        },
        {
          "facility": "Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny",
          "city": "Brzozów",
          "zip": "36-200",
          "country": "Poland",
          "geoPoint": {
            "lat": 49.69501,
            "lon": 22.01926
          }
        },
        {
          "facility": "Centrum Onkologii im. Prof. Franciszka ?ukaszczyka",
          "city": "Bydgoszcz",
          "zip": "85-796",
          "country": "Poland",
          "geoPoint": {
            "lat": 53.1235,
            "lon": 18.00762
          }
        },
        {
          "facility": "Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii",
          "city": "Krakow",
          "zip": "31-501",
          "country": "Poland",
          "geoPoint": {
            "lat": 50.06143,
            "lon": 19.93658
          }
        },
        {
          "facility": "Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu",
          "city": "Późna",
          "zip": "60-569",
          "country": "Poland",
          "geoPoint": {
            "lat": 51.84442,
            "lon": 14.61868
          }
        },
        {
          "facility": "National Cancer Center",
          "city": "Goyang-si",
          "zip": "10408",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.65639,
            "lon": 126.835
          }
        },
        {
          "facility": "Chonnam National University Hwasun Hospital",
          "city": "Jeollanam-do",
          "zip": "58128",
          "country": "South Korea"
        },
        {
          "facility": "Severance Hospital, Yonsei University Health System",
          "city": "Seoul",
          "zip": "03722",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Samsung Medical Center",
          "city": "Seoul",
          "zip": "06351",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Hospital Universitario Reina Sofia",
          "city": "Córdoba",
          "state": "Cordoba",
          "zip": "14004",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.89155,
            "lon": -4.77275
          }
        },
        {
          "facility": "Hospital de la Santa Creu i Sant Pau",
          "city": "Barcelona",
          "zip": "08025",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital Universitari Vall d'Hebron",
          "city": "Barcelona",
          "zip": "08035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital Universitario Ramon y Cajal",
          "city": "Madrid",
          "zip": "28034",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Universitario Clínico San Carlos",
          "city": "Madrid",
          "zip": "28040",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Universitario 12 de Octubre",
          "city": "Madrid",
          "zip": "28041",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Universitario Virgen del Rocio",
          "city": "Seville",
          "zip": "41013",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.38283,
            "lon": -5.97317
          }
        },
        {
          "facility": "Hospital Universitari i Politecnic La Fe",
          "city": "Valencia",
          "zip": "46026",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.47391,
            "lon": -0.37966
          }
        },
        {
          "facility": "Barts & London School of Med",
          "city": "London",
          "zip": "EC1A 7BE",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        },
        {
          "facility": "Christie Hospital Nhs Trust",
          "city": "Manchester",
          "zip": "M2O 4BX",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 53.48095,
            "lon": -2.23743
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\\_sharing"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-13"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D002292",
          "term": "Carcinoma, Renal Cell"
        }
      ],
      "ancestors": [
        {
          "id": "D000230",
          "term": "Adenocarcinoma"
        },
        {
          "id": "D002277",
          "term": "Carcinoma"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D007680",
          "term": "Kidney Neoplasms"
        },
        {
          "id": "D014571",
          "term": "Urologic Neoplasms"
        },
        {
          "id": "D014565",
          "term": "Urogenital Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D052776",
          "term": "Female Urogenital Diseases"
        },
        {
          "id": "D005261",
          "term": "Female Urogenital Diseases and Pregnancy Complications"
        },
        {
          "id": "D000091642",
          "term": "Urogenital Diseases"
        },
        {
          "id": "D007674",
          "term": "Kidney Diseases"
        },
        {
          "id": "D014570",
          "term": "Urologic Diseases"
        },
        {
          "id": "D052801",
          "term": "Male Urogenital Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000730814",
          "term": "Tiragolumab"
        },
        {
          "id": "C582435",
          "term": "pembrolizumab"
        },
        {
          "id": "D000077784",
          "term": "Axitinib"
        }
      ],
      "ancestors": [
        {
          "id": "D001549",
          "term": "Benzamides"
        },
        {
          "id": "D000577",
          "term": "Amides"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D001565",
          "term": "Benzoates"
        },
        {
          "id": "D000146",
          "term": "Acids, Carbocyclic"
        },
        {
          "id": "D002264",
          "term": "Carboxylic Acids"
        },
        {
          "id": "D001555",
          "term": "Benzene Derivatives"
        },
        {
          "id": "D006841",
          "term": "Hydrocarbons, Aromatic"
        },
        {
          "id": "D006844",
          "term": "Hydrocarbons, Cyclic"
        },
        {
          "id": "D006838",
          "term": "Hydrocarbons"
        },
        {
          "id": "D007191",
          "term": "Indazoles"
        },
        {
          "id": "D011720",
          "term": "Pyrazoles"
        },
        {
          "id": "D001393",
          "term": "Azoles"
        },
        {
          "id": "D006573",
          "term": "Heterocyclic Compounds, 1-Ring"
        },
        {
          "id": "D006571",
          "term": "Heterocyclic Compounds"
        },
        {
          "id": "D006574",
          "term": "Heterocyclic Compounds, 2-Ring"
        },
        {
          "id": "D000072471",
          "term": "Heterocyclic Compounds, Fused-Ring"
        }
      ]
    }
  },
  "hasResults": false
}